Cover Image
Market Research Report - 251306

Competitive Handbook towards Personalized Medicine in Prostate Cancer

Published by BioSeeker Group AB
Published Content info 1493 Pages
Price
Back to Top
Competitive Handbook towards Personalized Medicine in Prostate Cancer
Published: September 12, 2012 Content info: 1493 Pages
Description

Abstract

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis which allows you to discover:

  • Where the competition is; Which targets, compound types and companies are setting the path?
  • How much R&D effort has gone towards different targets and what is known about the target?
  • Which pathways are targeted, by what and how?
  • What is truly new and unique in the prostate cancer pipeline?
  • How new and unique your target strategy really is
  • What overlapping competition you have from other companies and compound types towards your therapeutic targets
  • Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:

  • 1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.
  • 2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.
  • 3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.
  • 4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

  • Head-to-head target competing analysis
  • Significant drug target overlap analysis
  • Cross-sectional R&D profiling of individual drug targets.
  • Cross-over analysis of target strategies among different compound types.
  • Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline:
    • Where are we?
    • Where is our general and specific competition?
    • What is the level of competition where we want to be?
    • 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company's interest in the prostate cancer pipeline by:

  • Better identifying benchmarking peers
  • Providing rationale for in/out licensing decisions of drug candidates
  • Performing proper drug due diligence
  • Strategies for commercial planning
  • Guiding Research & Development efforts
Table of Contents

Table of Contents

1. Executive Summary

2. About Cancer Highlights™

  • 2.1. Cancer Focus Areas
  • 2.2. Subscribe Today and Start Saving
    • 2.2.1. Type of License
  • 2.3. Additional Information
  • 2.4. BioSeeker Group's Oncology Team

3. Methodology

  • 3.1. Cancer Highlights'™ Five Pillar Drug Assessment

4. Table of Contents

  • 4.1. List of Figures
  • 4.2. List of Tables

5. Introduction

  • 5.1. The Scope of this Report
  • 5.2. Definitions
  • 5.3. Abbreviations

6. Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment

  • 6.1. Drug Repositioning in Oncology
  • 6.2. Introduction to Targets of Prostate Cancer Drugs
    • 6.2.1. Acid Phosphatase Activity Targets
    • 6.2.2. Auxiliary Transport Protein Activity Targets
    • 6.2.3. Calcium Ion Binding Targets
    • 6.2.4. Carboxy-lyase Activity Targets
    • 6.2.5. Carboxypeptidase Activity Targets
    • 6.2.6. Catalytic Activity Targets
    • 6.2.7. Cell Adhesion Molecule Activity Targets
    • 6.2.8. Chaperone Activity Targets
    • 6.2.9. Chemokine Activity Targets
    • 6.2.10. Complement Activity Targets
    • 6.2.11. Cysteine-type Peptidase Activity Targets
    • 6.2.12. Cytokine Activity Targets
    • 6.2.13. DNA Binding Targets
    • 6.2.14. DNA Repair Protein Targets
    • 6.2.15. DNA Topoisomerase Activity Targets
    • 6.2.16. DNA-directed DNA Polymerase Activity Targets
    • 6.2.17. Extracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.18. Extracellular Matrix Structural Constituent Targets
    • 6.2.19. G-protein Coupled Receptor Activity Targets
    • 6.2.20. Growth Factor Activity Targets
    • 6.2.21. GTPase Activator Activity Targets
    • 6.2.22. Hormone Activity Targets
    • 6.2.23. Hydrolase Activity Targets
    • 6.2.24. Intracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.25. Ion Channel Activity Targets
    • 6.2.26. Isomerase Activity Targets
    • 6.2.27. Kinase Activity Targets
    • 6.2.28. Ligand-dependent Nuclear Receptor Activity Targets
    • 6.2.29. Ligase Activity Targets
    • 6.2.30. Lipid Kinase Activity Targets
    • 6.2.31. Lipid Phosphatase Activity Targets
    • 6.2.32. Metallopeptidase Activity Targets
    • 6.2.33. MHC Class I Receptor Activity Targets
    • 6.2.34. Molecular Function Unknown Targets
    • 6.2.35. Motor Activity Targets
    • 6.2.36. Oxidoreductase Activity Targets
    • 6.2.37. Peptidase Activity Targets
    • 6.2.38. Peptide Hormone Targets
    • 6.2.39. Peroxidase Activity Targets
    • 6.2.40. Phosphoric Diester Hydrolase Activity Targets
    • 6.2.41. Protein Binding Targets
    • 6.2.42. Protein Serine/Threonine Kinase Activity Targets
    • 6.2.43. Protein Tyrosine Phosphatase Activity Targets
    • 6.2.44. Protein-tyrosine Kinase Activity Targets
    • 6.2.45. Receptor Activity Targets
    • 6.2.46. Receptor Binding Targets
    • 6.2.47. Receptor Signaling Complex Scaffold Activity Targets
    • 6.2.48. Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
    • 6.2.49. RNA Binding Targets
    • 6.2.50. RNA-directed DNA Polymerase Activity Targets
    • 6.2.51. Serine-type Peptidase Activity Targets
    • 6.2.52. Structural Constituent of Cytoskeleton Targets
    • 6.2.53. Superoxide Dismutase Activity Targets
    • 6.2.54. Transcription Factor Activity Targets
    • 6.2.55. Transcription Regulator Activity Targets
    • 6.2.56. Transferase Activity Targets
    • 6.2.57. Translation Regulator Activity Targets
    • 6.2.58. Transmembrane Receptor Activity Targets
    • 6.2.59. Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • 6.2.60. Transporter Activity Targets
    • 6.2.61. Ubiquitin-specific Protease Activity Targets
    • 6.2.62. Voltage-gated Ion Channel Activity Targets
    • 6.2.63. Other Targets
  • 6.3. Mutation Profiles of Prostate Cancer Drug Targets
    • 6.3.1. Targets of Prostate Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 6.4. Prostate Cancer Therapeutics is Stimulated by Available Structure Data on Targets
  • 6.5. Target-Target Interactions among Identified Targets of Prostate Cancer Drugs
  • 6.6. The Drug-Target Competitive Landscape
  • 6.7. Protein Expression Levels of Identified Targets of Prostate Cancer Drugs
  • 6.8. Pathway Assessment of Prostate Cancer Drugs
    • 6.8.1. Tools for Analysis of Cancer Pathways
    • 6.8.2. Pathway Assessment

7. Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development

  • 7.1. Pre-registrered and Marketed: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.2. Phase III Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.3. Phase II Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.4. Phase I Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.5. Preclinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.6. Drug Target Strategies of Suspended or Terminated Prostate Cancer Drugs
  • 7.7. Target Strategy Development Profiles of Prostate Cancer Drugs
    • 7.7.1. Marketed
    • 7.7.2. Pre-registration
    • 7.7.3. Phase III
    • 7.7.4. Phase II
    • 7.7.5. Phase I
    • 7.7.6. Preclinical
    • 7.7.7. No Data
    • 7.7.8. Suspended
    • 7.7.9. Ceased
  • 7.8. The Competition Through Close Mechanistic Approximation of Prostate Cancer Drugs

8. Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy

  • 8.1. Small Molecules
    • 8.1.1. Background
    • 8.1.2. Target Strategies of Small Molecule Drugs
  • 8.2. Peptide & Protein Drugs
    • 8.2.1. Background
    • 8.2.2. Target Strategies of Peptide and Protein Drugs
  • 8.3. Antibodies
    • 8.3.1. Background
    • 8.3.2. Target Strategies of Antibody Drugs
  • 8.4. Nucleic Acid Therapies
    • 8.4.1. Background
    • 8.4.2. Target Strategies of Nucleic Acid Drugs
  • 8.5. Cell & Gene Therapy
    • 8.5.1. Background
    • 8.5.2. Target Strategies of Cell and Gene Therapy Drugs
  • 8.6. Drug Delivery and Nanotechnology
    • 8.6.1. Background
    • 8.6.2. Target Strategies of Reformulated Drugs
  • 8.7. Compound Strategies based on Sub-Cellular Localization of Drug Targets

9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator

  • 9.1. Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
  • 9.2. Company Facts and Ranking
  • 9.3. Competitive Fall-Out Assessment
  • 9.4. Abbott
  • 9.5. Active Biotech
  • 9.6. Advantagene
  • 9.7. AEgera
  • 9.8. AEterna Zentaris
  • 9.9. Alchemia
  • 9.10. Alethia Biotherapeutics
  • 9.11. Allos Therapeutics
  • 9.12. AlphaVax
  • 9.13. Alseres Pharmaceuticals
  • 9.14. Altor BioScience
  • 9.15. Ambrilia Biopharma
  • 9.16. American Gene Technology International
  • 9.17. Amgen
  • 9.18. Anavex Life Sciences
  • 9.19. AndroBioSys
  • 9.20. Antisense Pharma
  • 9.21. Antisense Therapeutics
  • 9.22. Antisoma
  • 9.23. Aphios
  • 9.24. ApopLogic Pharmaceuticals
  • 9.25. Apotex
  • 9.26. Aprea
  • 9.27. Ardana
  • 9.28. Ariad
  • 9.29. ArQule
  • 9.30. Array BioPharma
  • 9.31. Ascenta Therapeutics
  • 9.32. Ascepion Pharmaceuticals
  • 9.33. Astellas
  • 9.34. Astex Pharmaceuticals
  • 9.35. AstraZeneca
  • 9.36. Attenuon
  • 9.37. AVI BioPharma
  • 9.38. Bavarian Nordic
  • 9.39. Baxter International
  • 9.40. Bayer
  • 9.41. Bellicum Pharmaceuticals
  • 9.42. Bioenvision
  • 9.43. Biogen Idec
  • 9.44. BioLineRx
  • 9.45. BioMarin
  • 9.46. BioNetWorks
  • 9.47. BioSante
  • 9.48. Biostar
  • 9.49. Boehringer Ingelheim
  • 9.50. Bristol-Myers Squibb
  • 9.51. BTG
  • 9.52. Camurus
  • 9.53. Cancer Research Technology
  • 9.54. Cel-Sci
  • 9.55. Celgene
  • 9.56. Cell Therapeutics
  • 9.57. Celldex Therapeutics
  • 9.58. Celsion
  • 9.59. Center of Molecular Immunology
  • 9.60. Cephalon
  • 9.61. Chemokine Therapeutics
  • 9.62. Circadian Technologies
  • 9.63. Cleveland BioLabs
  • 9.64. Colby
  • 9.65. Cosmo Bioscience
  • 9.66. Curaxis
  • 9.67. Curis
  • 9.68. Cylene Pharmaceuticals
  • 9.69. Cytokinetics
  • 9.70. Daiichi Sankyo
  • 9.71. Debiopharm
  • 9.72. Dendreon
  • 9.73. Dongkook Pharm
  • 9.74. ECI
  • 9.75. Eisai
  • 9.76. Eli Lilly
  • 9.77. Endo Pharmaceuticals
  • 9.78. Endocyte
  • 9.79. Ensemble Discovery
  • 9.80. EntreMed
  • 9.81. EpiCept
  • 9.82. Esperance Pharmaceuticals
  • 9.83. Etubics
  • 9.84. EUSA Pharma
  • 9.85. Exelixis
  • 9.86. Ferring
  • 9.87. Formula Pharmaceuticals
  • 9.88. Galena Biopharma
  • 9.89. Gemin X Pharmaceuticals
  • 9.90. Generex
  • 9.91. GENova Biotherapeutics
  • 9.92. Genovax
  • 9.93. Genta
  • 9.94. Gerolymatos
  • 9.95. Geron
  • 9.96. Gilead Sciences
  • 9.97. GlaxoSmithKline
  • 9.98. GlycoGenesys
  • 9.99. Got-a-Gene
  • 9.100. GP Pharm
  • 9.101. Green Cross
  • 9.102. GTx
  • 9.103. Harbor BioSciences
  • 9.104. Hoffmann-La Roche
  • 9.105. Human Genome Sciences
  • 9.106. IGF Oncology
  • 9.107. Immunocore
  • 9.108. ImmunoGen
  • 9.109. Immunomedics
  • 9.110. ImmuPharma
  • 9.111. Incyte Corporation
  • 9.112. Infinity Pharmaceuticals
  • 9.113. Inovio
  • 9.114. Insmed
  • 9.115. Insys Therapeutics
  • 9.116. Introgen Therapeutics
  • 9.117. Ipsen
  • 9.118. Isis Pharmaceuticals
  • 9.119. Ivy Medical Chemicals
  • 9.120. Johnson & Johnson
  • 9.121. Karo Bio
  • 9.122. Kinex
  • 9.123. Kyowa Hakko Kirin
  • 9.124. Leo
  • 9.125. Ligand
  • 9.126. Lorus Therapeutics
  • 9.127. Mannkind
  • 9.128. Marillion Pharmaceuticals
  • 9.129. Med Discovery
  • 9.130. Meda
  • 9.131. Medarex
  • 9.132. MediGene
  • 9.133. MedImmune
  • 9.134. Mediolanum
  • 9.135. Medivation
  • 9.136. Menarini
  • 9.137. Merck & Co
  • 9.138. Merck KGaA
  • 9.139. Merrion Pharmaceuticals
  • 9.140. MethylGene
  • 9.141. Mojave Therapeutics
  • 9.142. Molecular Insight
  • 9.143. Nektar Therapeutics
  • 9.144. Nereus Pharmaceuticals
  • 9.145. Nerviano Medical Sciences
  • 9.146. Neurocrine Biosciences
  • 9.147. Nippon Shinyaku
  • 9.148. Non-industrial Sources
  • 9.149. Northwest Biotherapeutics
  • 9.150. Novacea
  • 9.151. Novartis
  • 9.152. Novogen
  • 9.153. Oasmia
  • 9.154. OncoGenex Pharmaceuticals
  • 9.155. Oncothyreon
  • 9.156. Oncovir
  • 9.157. Orion Pharma
  • 9.158. OSI Pharmaceuticals
  • 9.159. Oxford BioMedica
  • 9.160. Paladin Labs
  • 9.161. Pantarhei Bioscience
  • 9.162. Pepscan Therapeutics
  • 9.163. Pfizer
  • 9.164. Pharmacyclics
  • 9.165. PharmaGap
  • 9.166. PharmaMar
  • 9.167. Philogen
  • 9.168. Pierre Fabre
  • 9.169. Progen
  • 9.170. Progenics Pharmaceuticals
  • 9.171. ProNAi Therapeutics
  • 9.172. ProStrakan
  • 9.173. Q Chip
  • 9.174. QLT
  • 9.175. Receptor BioLogix
  • 9.176. Regeneron
  • 9.177. Regulon
  • 9.178. Rexahn
  • 9.179. Salzburg Therapeutics
  • 9.180. Samyang
  • 9.181. Sanofi
  • 9.182. Santaris Pharma
  • 9.183. Sapphire Therapeutics
  • 9.184. SBIO
  • 9.185. SeleXel
  • 9.186. Semafore Pharmaceuticals
  • 9.187. Serometrix
  • 9.188. SGX Pharmaceuticals
  • 9.189. Shire
  • 9.190. Siena Biotech
  • 9.191. Soligenix
  • 9.192. Sophiris Bio
  • 9.193. SRI International
  • 9.194. Supratek Pharma
  • 9.195. Switch Pharma
  • 9.196. Synta Pharmaceuticals
  • 9.197. Taiho
  • 9.198. Takeda
  • 9.199. Tapestry Pharmaceuticals
  • 9.200. Tau Therapeutics
  • 9.201. Teva
  • 9.202. Thallion Pharmaceuticals
  • 9.203. Therion Biologics
  • 9.204. Titan Pharmaceuticals
  • 9.205. Tokai Pharmaceuticals
  • 9.206. TopoTarget
  • 9.207. Tracon Pharmaceuticals
  • 9.208. Transgene
  • 9.209. Twinstrand Therapeutics
  • 9.210. Unigene
  • 9.211. United Biomedical
  • 9.212. Vaxon Biotech
  • 9.213. Velacor Therapeutics
  • 9.214. Vical
  • 9.215. Vion Pharmaceuticals
  • 9.216. VioQuest
  • 9.217. Viralytics
  • 9.218. ViroTarg
  • 9.219. VM Discovery
  • 9.220. Wilex
  • 9.221. Xerion
  • 9.222. Xoma
  • 9.223. YM BioSciences
  • 9.224. Zydus Cadila

10. Disclaimer

11. Drug Index

12. Company Index

List of Figures

  • Figure 1: Visualization of Target-Target Interactions among Targets of Prostate Cancer Drugs
  • Figure 2: The Drug-Target Competitive Landscape of Prostate Cancer Drugs - Larger Clusters
  • Figure 3: The Drug-Target Competitive Landscape Prostate Cancer Drugs - Smaller Clusters
  • Figure 4: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs - Larger Clusters
  • Figure 5: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs - Smaller Clusters
  • Figure 6: Distribution of Compound Strategies among Prostate Cancer Drugs
  • Figure 7: Primary Sub-cellular Localization of Drug Targets
  • Figure 8: Number of Companies per Ranking Level

List of Tables

  • Table 1: Cancer Highlights'™ Five Pillar Drug Assessment
  • Table 2: Breakdown of the Included Prostate Cancer Drug Pipeline by Stage of Development
  • Table 3: Head to Head Target Competition among Prostate Cancer Drugs
  • Table 4: Overview of Drug Target Strategy Themes
  • Table 5: Terminally Ceased Targets of Prostate Cancer Drugs
  • Table 6: Official Gene Symbol to Target Profle
  • Table 7: Mutation Frequencies of Prostate Cancer Drug Targets
  • Table 8: Identity of Drug Targets with Available Biological Structures
  • Table 9: Number of Target-Target Interactions among Targets of Prostate Cancer Drugs
  • Table 10: Available Protein Expression Profiles of Prostate Cancer Drug Targets
  • Table 11: Pathway Summary
  • Table 12: Drug Targets without any Identified Assigned Pathways
  • Table 13: Pathway Profiles According to BioCarta of Prostate Cancer Drug Targets
  • Table 14: Pathway Profiles According to KEGG of Prostate Cancer Drug Targets
  • Table 15: Pathway Profiles According to NetPath of Prostate Cancer Drug Targets
  • Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
  • Table 17: Top Competitive Target Strategies of Prostate Cancer Drugs
  • Table 18: New and Unique Target Strategies of Prostate Cancer Drugs in Pre-registration or on the Marketed
  • Table 19: The Competition Through Close Mechanistic Approximation Between Prostate Cancer Drugs Being Marketed
  • Table 20: New and Unique Target Strategies in Phase III Clinical Development of Prostate Cancer Drugs
  • Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Prostate Cancer Drugs
  • Table 22: New and Unique Target Strategies in Phase II Clinical Development of Prostate Cancer Drugs
  • Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Prostate Cancer Drugs
  • Table 24: New and Unique Target Strategies in Phase I Clinical Development of Prostate Cancer Drugs
  • Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Prostate Cancer Drugs
  • Table 26: New and Unique Target Strategies in Preclinical Development of Prostate Cancer Drugs
  • Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Prostate Cancer Drugs
  • Table 28: Target Strategies of No Data, Suspended or Terminated Prostate Cancer Drugs
  • Table 29: Connecting Target Strategy with Its Profile Identification Number
  • Table 30: The Competition Through Close Mechanistic Approximation Among Prostate Cancer Drugs
  • Table 31: Overview of Compound Strategy Competition Among Prostate Cancer Drugs
  • Table 32: Overview of the Competitive Landscape of Small Molecule Based Prostate Cancer Drugs
  • Table 33: Competitive Comparison of Target Strategies of Small Molecule Prostate Cancer Drugs
  • Table 34: Pursued Target Strategies of Small Molecule Drugs Based Prostate Cancer Drugs
  • Table 35: Overview of the Competitive Landscape of Peptide Based Prostate Cancer Drugs
  • Table 36: Competitive Comparison of Target Strategies of Peptide Based Prostate Cancer Drugs
  • Table 37: Pursued Target Strategies of Peptide Based Prostate Cancer Drugs
  • Table 38: Overview of the Competitive Landscape of Protein Based Prostate Cancer Drugs
  • Table 39: Competitive Comparison of Target Strategies of Protein Based Prostate Cancer Drugs
  • Table 40: Pursued Target Strategies of Protein Based Prostate Cancer Drugs
  • Table 41: Overview of the Competitive Landscape of Antibody Based Prostate Cancer Drugs
  • Table 42: Competitive Comparison of Target Strategies of Antibody Based Prostate Cancer Drugs
  • Table 43: Pursued Target Strategies of Antibody Based Prostate Cancer Drugs
  • Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Prostate Cancer Drugs
  • Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Prostate Cancer Drugs
  • Table 46: Pursued Target Strategies of Nucleic Acid Based Prostate Cancer Drugs
  • Table 47: Potential Forms of Cell Therapy
  • Table 48: Vectors in Gene Therapy
  • Table 49: Overview of the Competitive Landscape of Cell Therapy Based Prostate Cancer Drugs
  • Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Prostate Cancer Drugs
  • Table 51: Pursued Target Strategies of Cell Therapy Based Prostate Cancer Drugs
  • Table 52: Overview of the Competitive Landscape of Gene Therapy Based Prostate Cancer Drugs
  • Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Prostate Cancer Drugs
  • Table 54: Pursued Target Strategies of Gene Therapy Based Prostate Cancer Drugs
  • Table 55:Overview of the Competitive Landscape of Reformulated Prostate Cancer Drugs
  • Table 56: Competitive Comparison of Target Strategies of Reformulated Prostate Cancer Drugs
  • Table 57: Pursued Target Strategies of Reformulated Prostate Cancer Drugs
  • Table 58: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets
  • Table 59: Competitive Summary by Investigator of Prostate Cancer Drug Development
  • Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Prostate Cancer Drug Development
  • Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters
  • Table 62: Example of a Competitive Fall-Out Table (Targeting TOP2A)
  • Table 63: Abbott's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 64: Active Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 65: Advantagene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 66: AEgera's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 67: AEterna Zentaris' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 68: Alchemia's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 69: Alethia Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 70: Allos Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 71: AlphaVax's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 72: Alseres Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 73: Altor BioScience's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 74: Ambrilia Biopharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 75: American Gene Technology International's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 76: Amgen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 77: Anavex Life Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 78: AndroBioSys' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 79: Antisense Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 80: Antisense Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 81: Antisoma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 82: Aphios' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 83: ApopLogic Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 84: Apotex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 85: Aprea's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 86: Ardana's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 87: Ariad's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 88: ArQule's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 89: Array BioPharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 90: Ascenta Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 91: Ascepion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 92: Astellas' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 93: Astex Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 94: AstraZeneca's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 95: Attenuon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 96: AVI BioPharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 97: Bavarian Nordic's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 98: Baxter International's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 99: Bayer's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 100: Bellicum Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 101: Bioenvision's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 102: Biogen Idec's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 103: BioLineRx's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 104: BioMarin's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 105: BioNetWorks' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 106: BioSante's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 107: Biostar's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 108: Boehringer Ingelheim's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 109: Bristol-Myers Squibb's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 110: BTG's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 111: Camurus' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 112: Cancer Research Technology's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 113: Cel-Sci's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 114: Celgene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 115: Cell Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 116: Celldex Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 117: Celsion's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 118: Center of Molecular Immunology's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 119: Cephalon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 120: Chemokine Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 121: Circadian Technologies' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 122: Cleveland BioLabs' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 123: Colby's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 124: Cosmo Bioscience's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 125: Curaxis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 126: Curis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 127: Cylene Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 128: Cytokinetics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 129: Daiichi Sankyo's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 130: Debiopharm's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 131: Dendreon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 132: Dongkook Pharm's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 133: ECI's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 134: Eisai's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 135: Eli Lilly's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 136: Endo Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 137: Endocyte's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 138: Ensemble Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 139: EntreMed's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 140: EpiCept's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 141: Esperance Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 142: Etubics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 143: EUSA Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 144: Exelixis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 145: Ferring's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 146: Formula Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 147: Galena Biopharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 148: Gemin X Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 149: Generex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 150: GENova Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 151: Genovax's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 152: Genta's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 153: Gerolymatos' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 154: Geron's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 155: Gilead Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 156: GlaxoSmithKline's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 157: GlycoGenesys' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 158: Got-a-Gene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 159: GP Pharm's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 160: Green Cross' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 161: GTx's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 162: Harbor BioSciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 163: Hoffmann-La Roche's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 164: Human Genome Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 165: IGF Oncology's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 166: Immunocore's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 167: ImmunoGen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 168: Immunomedics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 169: ImmuPharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 170: Incyte Corporation's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 171: Infinity Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 172: Inovio's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 173: Insmed's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 174: Insys Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 175: Introgen Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 176: Ipsen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 177: Isis Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 178: Ivy Medical Chemicals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 179: Johnson & Johnson's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 180: Karo Bio's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 181: Kinex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 182: Kyowa Hakko Kirin's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 183: Leo's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 184: Ligand's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 185: Lorus Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 186: Mannkind's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 187: Marillion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 188: Med Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 189: Meda's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 190: Medarex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 191: MediGene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 192: MedImmune's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 193: Mediolanum's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 194: Medivation's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 195: Menarini's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 196: Merck & Co's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 197: Merck KGaA's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 198: Merrion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 199: MethylGene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 200: Mojave Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 201: Molecular Insight's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 202: Nektar Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 203: Nereus Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 204: Nerviano Medical Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 205: Neurocrine Biosciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 206: Nippon Shinyaku's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 207: Non-industrial source's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 208: Northwest Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 209: Novacea's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 210: Novartis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 211: Novogen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 212: Oasmia's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 213: OncoGenex Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 214: Oncothyreon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 215: Oncovir's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 216: Orion Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 217: OSI Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 218: Oxford BioMedica's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 219: Paladin Labs' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 220: Pantarhei Bioscience's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 221: Pepscan Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 222: Pfizer's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 223: Pharmacyclics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 224: PharmaGap's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 225: PharmaMar's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 226: Philogen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 227: Pierre Fabre's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 228: Progen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 229: Progenics Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 230: ProNAi Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 231: ProStrakan's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 232: Q Chip's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 233: QLT's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 234: Receptor BioLogix's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 235: Regeneron's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 236: Regulon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 237: Rexahn's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 238: Salzburg Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 239: Samyang's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 240: Sanofi's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 241: Santaris Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 242: Sapphire Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 243: SBIO's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 244: SeleXel's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 245: Semafore Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 246: Serometrix's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 247: SGX Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 248: Shire's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 249: Siena Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 250: Soligenix's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 251: Sophiris Bio's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 252: SRI International's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 253: Supratek Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 254: Switch Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 255: Synta Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 256: Taiho's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 257: Takeda's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 258: Tapestry Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 259: Tau Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 260: Teva's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 261: Thallion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 262: Therion Biologics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 263: Titan Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 264: Tokai Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 265: TopoTarget's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 266: Tracon Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 267: Transgene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 268: Twinstrand Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 269: Unigene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 270: United Biomedical's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 271: Vaxon Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 272: Velacor Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 273: Vical's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 274: Vion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 275: VioQuest's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 276: Viralytics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 277: ViroTarg's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 278: VM Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 279: Wilex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 280: Xerion's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 281: Xoma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 282: YM BioSciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 283: Zydus Cadila's Included Prostate Cancer Drugs and Competitive Fall-Out

This report includes 222 companies (Incl. Active, Out of Business and M&A) plus their collaborators:

  • Abbott
  • Active Biotech
  • Advantagene
  • AEgera
  • AEterna Zentaris
  • Alchemia
  • Alethia Biotherapeutics
  • Allos Therapeutics
  • AlphaVax
  • Alseres Pharmaceuticals
  • Altor BioScience
  • Ambrilia Biopharma
  • American Gene Technology International
  • Amgen
  • Anavex Life Sciences
  • AndroBioSys
  • Antisense Pharma
  • Antisense Therapeutics
  • Antisoma
  • Aphios
  • ApopLogic Pharmaceuticals
  • Apotex
  • Aprea
  • Ardana
  • Ariad
  • ArQule
  • Array BioPharma
  • Ascenta Therapeutics
  • Ascepion Pharmaceuticals
  • Astellas
  • Astex Pharmaceuticals
  • AstraZeneca
  • Attenuon
  • AVI BioPharma
  • Bavarian Nordic
  • Baxter International
  • Bayer
  • Bellicum Pharmaceuticals
  • Bioenvision
  • Biogen Idec
  • BioLineRx
  • BioMarin
  • BioNetWorks
  • BioSante
  • Biostar
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Camurus
  • Cancer Research Technology
  • Celgene
  • Cell Therapeutics
  • Celldex Therapeutics
  • Cel-Sci
  • Celsion
  • Center of Molecular Immunology
  • Cephalon
  • Chemokine Therapeutics
  • Circadian Technologies
  • Cleveland BioLabs
  • Colby
  • Cosmo Bioscience
  • Curaxis
  • Curis
  • Cylene Pharmaceuticals
  • Cytokinetics
  • Daiichi Sankyo
  • Debiopharm
  • Dendreon
  • Dongkook Pharm
  • ECI
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Endocyte
  • Ensemble Discovery
  • EntreMed
  • EpiCept
  • Esperance Pharmaceuticals
  • Etubics
  • EUSA Pharma
  • Exelixis
  • Ferring
  • Formula Pharmaceuticals
  • Galena Biopharma
  • Gemin X Pharmaceuticals
  • Generex
  • GENova Biotherapeutics
  • Genovax
  • Genta
  • Gerolymatos
  • Geron
  • Gilead Sciences
  • GlaxoSmithKline
  • GlycoGenesys
  • Got-a-Gene
  • GP Pharm
  • Green Cross
  • GTx
  • Harbor BioSciences
  • Hoffmann-La Roche
  • Human Genome Sciences
  • IGF Oncology
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • ImmuPharma
  • Incyte Corporation
  • Infinity Pharmaceuticals
  • Inovio
  • Insmed
  • Insys Therapeutics
  • Introgen Therapeutics
  • Ipsen
  • Isis Pharmaceuticals
  • Ivy Medical Chemicals
  • Johnson & Johnson
  • Karo Bio
  • Kinex
  • Kyowa Hakko Kirin
  • Leo
  • Ligand
  • Lorus Therapeutics
  • Mannkind
  • Marillion Pharmaceuticals
  • Med Discovery
  • Meda
  • Medarex
  • MediGene
  • MedImmune
  • Mediolanum
  • Medivation
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merrion Pharmaceuticals
  • MethylGene
  • Mojave Therapeutics
  • Molecular Insight
  • Nektar Therapeutics
  • Nereus Pharmaceuticals
  • Nerviano Medical Sciences
  • Neurocrine Biosciences
  • Nippon Shinyaku
  • Non-industrial source
  • Northwest Biotherapeutics
  • Novacea
  • Novartis
  • Novogen
  • Oasmia
  • OncoGenex Pharmaceuticals
  • Oncothyreon
  • Oncovir
  • Orion Pharma
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • Paladin Labs
  • Pantarhei Bioscience
  • Pepscan Therapeutics
  • Pfizer
  • Pharmacyclics
  • PharmaGap
  • PharmaMar
  • Philogen
  • Pierre Fabre
  • Progen
  • Progenics Pharmaceuticals
  • ProNAi Therapeutics
  • ProStrakan
  • Q Chip
  • QLT
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • Rexahn
  • Salzburg Therapeutics
  • Samyang
  • Sanofi
  • Santaris Pharma
  • Sapphire Therapeutics
  • SBIO
  • SeleXel
  • Semafore Pharmaceuticals
  • Serometrix
  • SGX Pharmaceuticals
  • Shire
  • Siena Biotech
  • Soligenix
  • Sophiris Bio
  • SRI International
  • Supratek Pharma
  • Switch Pharma
  • Synta Pharmaceuticals
  • Taiho
  • Takeda
  • Tapestry Pharmaceuticals
  • Tau Therapeutics
  • Teva
  • Thallion Pharmaceuticals
  • Therion Biologics
  • Titan Pharmaceuticals
  • Tokai Pharmaceuticals
  • TopoTarget
  • Tracon Pharmaceuticals
  • Transgene
  • Twinstrand Therapeutics
  • Unigene
  • United Biomedical
  • Vaxon Biotech
  • Velacor Therapeutics
  • Vical
  • Vion Pharmaceuticals
  • VioQuest
  • Viralytics
  • ViroTarg
  • VM Discovery
  • Wilex
  • Xerion
  • Xoma
  • YM BioSciences
  • Zydus Cadila

This report includes 394 prostate cancer drugs. From Ceased to Marketed.

Some examples are:

  • abarelix
  • abiraterone acetate
  • adecatumumab
  • aderbasib
  • AEZS-108
  • afatinib
  • aflibercept
  • ALT-801
  • alvocidib
  • amonafide dihydrochloride
  • amonafide malate
  • APC-100
  • APR-246
  • ARC-100
  • atrasentan
  • AVX-701
  • bafetinib
  • bevacizumab
  • BIBF-1120
  • bicalutamide
  • BMS-777607
  • BMS-936558
  • bortezomib
  • BP-GMAX-CD1
  • buserelin
  • Cabozantinib
  • carlumab
  • cediranib
  • celecoxib
  • cetuximab
  • cixutumumab
  • custirsen
  • danusertib
  • dasatinib
  • DCVax-prostate
  • degarelix
  • denosumab
  • deslorelin
  • DI-17E6
  • docetaxel
  • dovitinib lactate
  • doxercalciferol
  • doxorubicin
  • dutasteride
  • E-75
  • entinostat
  • enzastaurin hydrochloride
  • estramustine phosphate sodium
  • ethinyl estradiol sulfonate
  • everolimus
  • figitumumab
  • flutamide
  • fulvestrant
  • gataparsen
  • GDC-0980
  • gefitinib
  • goserelin (1)
  • GTx-758
  • GVAX
  • GVX-3322
  • GX-301
  • HE-3235
  • histrelin
  • idronoxil
  • imatinib mesilate
  • inecalcitol
  • INSM-18
  • interleukins
  • intetumumab
  • ipilimumab
  • irosustat
  • ispinesib mesylate
  • KX2-391
  • lapatinib ditosylate
  • lestaurtinib
  • leucine-doxorubicin
  • leuprolide
  • leuprolide acetate
  • leuprorelin acetate
  • LIP-131I
  • LipoVIL12
  • litronesib
  • LOR-2040
  • LOR-2501
  • LY-2275796
  • MCS-110
  • MDV-3100
  • MLN-8237
  • Nab-docetaxel
  • nadroparin
  • nilutamide
  • nimotuzumab
  • oblimersen sodium
  • OGX-427
  • olaparib
  • olaratumab
  • orteronel
  • ozarelix
  • paclitaxel
  • paclitaxel polyglumex
  • panitumumab
  • panobinostat
  • perifosine
  • pertuzumab
  • plitidepsin
  • PLX-3397
  • ProstAtak
  • PROSTVAC
  • PRX-302
  • PX-866
  • quarfloxacin
  • quinacrine
  • R-(-)-gossypol
  • ramucirumab
  • retaspimycin
  • ridaforolimus
  • rilotumumab
  • romidepsin
  • ruxolitinib
  • sagopilone
  • sargramostim
  • SB-939
  • siltuximab
  • sipuleucel-T
  • sorafenib tosylate
  • TAK-448
  • tandutinib
  • tasquinimod
  • telomerase vaccine
  • temsirolimus
  • Tenarad
  • TOK-001
  • toremifene citrate
  • TRC-105
  • tremelimumab
  • trilostane
  • triptorelin
  • TroVax
  • TS-1
  • tucotuzumab celmoleukin
  • vandetanib
  • YM-155
  • zibotentan
Back to Top